Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Tools
Tools
Piga, Antonio, Galanello, Renzo, Forni, Gian Luca, Cappellini, Maria Domenica, Origa, Raffaella, Zappu, Antonietta, Donato, Guido, Bordone, Elena, Lavagetto, Antonella, Zanaboni, Laura, Sechaud, Romain, Hewson, Nicola, Ford, John M, Opitz, Herbert and Alberti, Daniele (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 91 (7). pp. 873-880. ISSN 1592-8721
Abstract
Iron accumulation is an inevitable consequence of chronic blood transfusions and results in serious complications in the absence of chelation treatment to remove excess iron. Deferoxamine (Desferal, DFO) reduces morbidity and mortality although the administration schedule of slow, parenteral infusions several days each week limits compliance and negatively affects long-term outcome. Deferasirox (Exjade, ICL670) is an oral chelator with high iron-binding potency and selectivity. In a phase II study, the tolerability and efficacy of deferasirox were compared with those of DFO in 71 adults with transfusional hemosiderosis.
| Item Type: | Article |
|---|---|
| Related URLs: | |
| Related URLs: | |
| Date Deposited: | 05 Oct 2012 23:45 |
| Last Modified: | 05 Oct 2012 23:45 |
| URI: | https://oak.novartis.com/id/eprint/8696 |